Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.12 USD

96.12
370,120

+0.08 (0.08%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.

Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Investors' optimism continues to be high on solid prospects of Hill-Rom Holdings (HRC).

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

Here's Why You Should Consider Betting on CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Henry Schein Expands SolutionsHub With CueSquared MobilePay

by Zacks Equity Research

The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on ResMed's (RMD) prospects.

Haemonetics Rides on Strong Plasma and Global Expansion

by Zacks Equity Research

Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Medtronic (MDT) Benefits from Strength Across Business Groups

by Zacks Equity Research

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investor confidence is currently high on NuVasive's (NUVA) prospects.

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

by Zacks Equity Research

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why You Should Invest in DaVita (DVA) Stock For Now

by Zacks Equity Research

DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.

Here's Why You Should Retain Nevro (NVRO) in Your Portfolio

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space. However, forex remains a woe.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Trina Mukherjee headshot

Outlook for Outpatient and Home Healthcare Industry Looks Bright

by Trina Mukherjee

Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.

Moving Average Crossover Alert: Amedisys

by Zacks Equity Research

Amedisys, Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.